Indivior reported 962M in Current Liabilities for its fiscal quarter ending in September of 2024.

Current Liabilities Change Date
AstraZeneca USD 27.87B 1.94B Dec/2024
Eli Lilly USD 24.67B 2.45B Sep/2024
Glaxosmithkline GBP 21.46B 1.11B Sep/2024
Halozyme Therapeutics USD 139.1M 30.28M Dec/2024
Indivior 962M 50M Sep/2024
J&J USD 51.76B 2.17B Sep/2024
Kyowa Hakko Kirin JPY 164.68B 8.99B Dec/2024
Merck USD 29.59B 3.53B Sep/2024
Novartis USD 28.13B 520M Sep/2024
Pfizer USD 43.21B 608M Sep/2024
Sanofi 30.03B 5.82B Jun/2024
Supernus Pharmaceuticals USD 291.51M 17.15M Sep/2024